Name | STING agonist-1 |
---|---|
Synonyms |
G10 [PMID: 26646986]
2H-1,4-Benzothiazine-6-carboxamide, 4-[(2-chloro-6-fluorophenyl)methyl]-N-(2-furanylmethyl)-3,4-dihydro-3-oxo- 4-(2-Chloro-6-fluorobenzyl)-N-(2-furylmethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide MFCD04062826 |
Description | STING agonist-1 (G10) is a novel human-specific STING agonist that elicits antiviral activity against emerging Alphaviruses. G10 potently blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) (IC90 = 24.57 μM). IC50 value: 24.57 μM (IC90)Target: VEEV, STINGin vitro: G10 does not bind to STING directly, however, G10 represents the first synthetic small molecule characterized as an indirect activator of human STING-dependent phenotypes.100 μM G10 (a concentration over twelve times the IC90 for CHIKV and over four times the IC90 for VEEV). G10 induces IFN/IRF3- but not NF-κB-dependent transcription in human fibroblasts. G10 Induces IFN/IRF3- but not NF-κB-Dependent Transcription in Human Fibroblasts. G10 activates IRF3, but not canonical NF-κB pathways in human fibroblasts. G10 elicits antiviral activity against New and Old World Alphaviruses. G10 stimulates phosphorylation of IFN regulatory factor 3 (IRF3) in a manner similar to that triggered by UV-inactivated cytomegalovirus (UV-CMV) and Sendai virus (SeV). G10 induces synthesis and secretion of bioactive type I and III IFNs and generates an antiviral state in fibroblast cells positive for STING, IRF3, and STAT1 proteins. G10 triggers innate immune responses that involve expression of IRF3-dependent genes including type I and III interferons. |
---|---|
Related Catalog | |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 668.3±55.0 °C at 760 mmHg |
Molecular Formula | C21H16ClFN2O3S |
Molecular Weight | 430.880 |
Flash Point | 358.0±31.5 °C |
Exact Mass | 430.055420 |
LogP | 3.41 |
Vapour Pressure | 0.0±2.0 mmHg at 25°C |
Index of Refraction | 1.651 |
Storage condition | 2-8℃ |